Fibrinogen (Fg), i. e. coagulation factor I, molecular weight about 340kDa, by α, β, γ three pairs of different polypeptide chain. Polypeptide chains are linked by disulfide bonds. Protein Content: 67.30.
FINO2 is a potent ferroptosis inducer. FINO2 inhibits GPX4 activity. FINO2 is a stable oxidant that oxidizes ferrous iron and stable at varying pH levels. FINO2 causes widespread lipid peroxidation.
BC1618, an orally active Fbxo48 inhibitor, stimulates Ampk signaling (preventing activated pAmpkα from being degraded by fBXO48-mediated proteasome). BC1618 promotes mitochondrial division, autophagy and insulin sensitivity in the liver.
Blu-945 is a potent inhibitor of selective epidermal growth factor receptor (EGFR). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation.
Sunvozertinib (DZD9008) is an effective inhibitor of ErbBs (EGFR, Her2, especially mutants) and BTK.
3-amino-propanonitrile (β -amino-propanonitrile (BAPN)) acts as an irreversible inhibitor of lysyl oxidase (LOX), an enzyme involved in collagen cross-linking.
Palifosfamide(Isophosphoramide mustard; IPM; Zio-201) is a new DNA alkylation agent and active metabolite of isocyclophosphamide, which has anticancer activity.
Deschloroclozapine is an effective, high affinity, selective, metabolically stable agonist based on muscarinic DREADDs. The Ki binding values of Deschloroclozapine to DREADD receptor subtypes hM3Dq and hM4Di were 6.3 and 4.2 nM, respectively.
3-amino-propanonitrile (β -amino-propanonitrile (BAPN)) acts as an irreversible inhibitor of lysyl oxidase (LOX), an enzyme involved in collagen cross-linking.
Letermovir (AIC246) is a novel and potent anti-CMV compound that targets viral terminal enzyme complexes and is active in viruses that are resistant to DNA polymerase inhibitors.
Letermovir (AIC246) is a novel and potent anti-CMV compound that targets viral terminal enzyme complexes and is active in viruses that are resistant to DNA polymerase inhibitors.
ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.